Botulinum Toxin Application in the Medical Aesthetics Industry

Dear Colleagues,

Botulinum neurotoxin injection is one of the most massively used modalities in aesthetic medicine and surgery. Currently, there are various injectable botulinum neurotoxin products worldwide. Different products show different pharmacologic characteristics, while many features are shared. Some products eliminate non-toxin proteins to reduce risk of antibody formation. Some new products exist in ready-to-inject liquid form. The diversity of the botulinum neurotoxin products in the market suggests that there should be a summary to characterise and compare each product. This Special Issue aims to provide an update on the current status of botulinum toxin products in the field and their clinical applications in the context of aesthetic medicine and surgery.

Potential topics include (but are not limited to) the following:

- Review of the product comparison;

- Clinical consensus and practice guidelines on the use a specific neurotoxin product;

- Off-facial or non-conventional aesthetic indications of botulinum neurotoxin;

- Position statements on medical, legal, and cultural issues related to aesthetic uses of botulinum toxin;

- Early reports on the clinical use of newly developed products;

- Development of new botulinum toxin formulations;

- Market analysis and forecast.

Dr. Nark-Kyoung Rho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.